Risk of Premature Ovarian Insufficiency after Human Papilloma Virus Vaccination: A PRISMA Systematic Review and Meta-Analysis of Current Evidence
Abstract
:1. Introduction
2. Materials and Methods
2.1. Data Sources and Search Strategy
2.2. Study Selection Criteria and Data Extraction
2.3. Main Outcome Measures
2.4. Assessment of Risk of Bias
2.5. Data Analysis
3. Results
3.1. Quality Assessment
3.2. Synthesis of Results
3.3. Subgroup Analysis
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bednarczyk, R.A. Addressing HPV vaccine myths: Practical information for healthcare providers. Hum. Vaccin. Immunother. 2019, 15, 1628–1638. [Google Scholar] [CrossRef] [PubMed]
- Schettino, M.T.; Ammaturo, F.P.; Grimaldi, E.; Legnante, A.; Marcello, A.; Donnarumma, G.; Colacurci, N.; Torella, M. Persistent papillomavirus type-31 and type-45 infections predict the progression to squamous intraepithelial lesion. Taiwan J. Obstet. Gynecol. 2014, 53, 494–497. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oliver, K.; Frawley, A.; Garland, E. HPV vaccination: Population approaches for improving rates. Hum. Vaccin. Immunother. 2016, 12, 1589–1593. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Naleway, A.L.; Mittendorf, K.F.; Irving, S.A.; Henninger, M.L.; Crane, B.; Smith, N.; Daley, M.F.; Gee, J. Primary Ovarian Insufficiency and Adolescent Vaccination. Pediatrics 2018, 142, e20180943. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Holman, D.M.; Benard, V.; Roland, K.B.; Watson, M.; Liddon, N.; Stokley, S. Barriers to human papillomavirus vaccination among US adolescents: A systematic review of the literature. JAMA Pediatr. 2014, 168, 76–82. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Little, D.T.; Ward, H.R. Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination. BMJ Case Rep. 2012, 2012, bcr2012006879. [Google Scholar] [CrossRef] [Green Version]
- Torella, M.; Riemma, G.; De Franciscis, P.; La Verde, M.; Colacurci, N. Serum Anti-Mullerian Hormone Levels and Risk of Premature Ovarian Insufficiency in Female Childhood Cancer Survivors: Systematic Review and Network Meta-Analysis. Cancers 2021, 13, 6331. [Google Scholar] [CrossRef]
- Karska, P.; Matonog, A.; Sieradzka, P.; Kowalczyk, K.; Madej, P. Fresh insight into premature ovarian insufficiency. Ginekol. Pol. 2021, 92, 518–524. [Google Scholar] [CrossRef]
- Golezar, S.; Ramezani Tehrani, F.; Khazaei, S.; Ebadi, A.; Keshavarz, Z. The global prevalence of primary ovarian insufficiency and early menopause: A meta-analysis. Climacteric 2019, 22, 403–411. [Google Scholar] [CrossRef]
- Panay, N.; Anderson, R.A.; Nappi, R.E.; Vincent, A.J.; Vujovic, S.; Webber, L.; Wolfman, W. Premature ovarian insufficiency: An International Menopause Society White Paper. Climacteric 2020, 23, 426–446. [Google Scholar] [CrossRef]
- Pellegrino, P.; Carnovale, C.; Perrone, V.; Salvati, D.; Gentili, M.; Brusadelli, T.; Pozzi, M.; Antoniazzi, S.; Clementi, E.; Radice, S. On the association between human papillomavirus vaccine and primary ovarian failure. Am. J. Reprod. Immunol. 2014, 71, 293–294. [Google Scholar] [CrossRef] [PubMed]
- Hawkes, D.; Buttery, J.P. Human papillomavirus vaccination and primary ovarian insufficiency: An association based on ideology rather than evidence. Curr. Opin. Obstet. Gynecol. 2016, 28, 70–72. [Google Scholar] [CrossRef] [PubMed]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
- Margulis, A.V.; Pladevall, M.; Riera-Guardia, N.; Varas-Lorenzo, C.; Hazell, L.; Berkman, N.D.; Viswanathan, M.; Perez-Gutthann, S. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: The Newcastle-Ottawa Scale and the RTI item bank. Clin. Epidemiol. 2014, 6, 359–368. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hviid, A.; Myrup Thiesson, E. Association Between Human Papillomavirus Vaccination and Primary Ovarian Insufficiency in a Nationwide Cohort. JAMA Netw. Open 2021, 4, e2120391. [Google Scholar] [CrossRef]
- Phillips, A.; Hickie, M.; Totterdell, J.; Brotherton, J.; Dey, A.; Hill, R.; Snelling, T.; Macartney, K. Adverse events following HPV vaccination: 11 years of surveillance in Australia. Vaccine 2020, 38, 6038–6046. [Google Scholar] [CrossRef]
- Gong, L.; Ji, H.H.; Tang, X.W.; Pan, L.Y.; Chen, X.; Jia, Y.T. Human papillomavirus vaccine-associated premature ovarian insufficiency and related adverse events: Data mining of Vaccine Adverse Event Reporting System. Sci. Rep. 2020, 10, 10762. [Google Scholar] [CrossRef]
- Armeni, E.; Paschou, S.A.; Goulis, D.G.; Lambrinoudaki, I. Hormone therapy regimens for managing the menopause and premature ovarian insufficiency. Best Pract. Res. Clin. Endocrinol. Metab. 2021, 35, 101561. [Google Scholar] [CrossRef]
- Little, D.T.; Ward, H.R. Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice. J. Investig. Med. High Impact Case Rep. 2014, 2, 2324709614556129. [Google Scholar] [CrossRef] [Green Version]
- Hawkes, D. Evidence evolves over time and should be based on data not opinion. BMJ Evid. Based Med. 2020, 25, 191–192. [Google Scholar] [CrossRef]
- Del Giudice, G.; Rappuoli, R.; Didierlaurent, A.M. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin. Immunol. 2018, 39, 14–21. [Google Scholar] [CrossRef] [PubMed]
- Demir, M.; Ince, O.; Yilmaz, B.; Decleer, W.; Osmanagaoglu, K. The effect of human papilloma virus vaccination on embryo yield and clinical in vitro fertilisation outcomes: A matched retrospective cohort study. J. Obstet. Gynaecol. 2021, 41, 421–427. [Google Scholar] [CrossRef] [PubMed]
- Tatang, C.; Arredondo Bisono, T.; Bergamasco, A.; Salvo, F.; Costa Clemens, S.A.; Moride, Y. Human Papillomavirus Vaccination and Premature Ovarian Failure: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System. Drugs Real World Outcomes 2022, 9, 79–90. [Google Scholar] [CrossRef] [PubMed]
Study, Year | Design | Location | Duration | Population | Intervention | Control | Outcomes | Sample Size |
---|---|---|---|---|---|---|---|---|
Gong, 2020 [17] | Retrospective cohort study | China | 2006–2018 | 9–18 years old females | 4vHPV | 2vHPV 9vHPV | Diagnoses of POI and related symptoms | 418 |
Hviid, 2021 [15] | Retrospective cohort study | Denmark | 2007–2016 | Girls aged between 12–15 | 4vHPV vaccination | Unvaccinated girls | Diagnoses of POI | 1,051,041 |
Naleway, 2018 [4] | Retrospective cohort study | USA | 2006–2014 | NA | HPV vaccinated girls | Other vaccine (tetanus toxoid, Tdap, influenza) | Risk of POI | 199,078 |
Phillips, 2020 [16] | Retrospective cohort study | Australia | 2007–2017 | 12–13 years old male and female children | 4vHPV vaccination | Unvaccinated children | Adverse events of special interest following 4vHPV vaccination | 3221 |
Study, Year | Inclusion Criteria | Exclusion Criteria |
---|---|---|
Gong, 2020 [17] | Women inserted in the HPV- vaccine-related adverse events | NA |
Hviid, 2021 [15] | Women added in a register-based research study of all Danish-born girls and women aged 11 to 34 years during 2007 to 2016. | NA |
Naleway, 2018 [4] | Women with premature ovarian insufficiency from a non-genetic cause | Premature ovarian insufficiency from other known causes (fragile X Syndrome, Turner Syndrome or other chromosomal disorders) |
Phillips, 2020 [16] | Women with a severe adverse event following 4vHPV vaccination | Women with an adverse event following 9vHPV or 2vHPV HPV vaccines. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Torella, M.; Marrapodi, M.M.; Ronsini, C.; Ruffolo, A.F.; Braga, A.; Frigerio, M.; Amabile, E.; Vastarella, M.G.; Rossi, F.; Riemma, G. Risk of Premature Ovarian Insufficiency after Human Papilloma Virus Vaccination: A PRISMA Systematic Review and Meta-Analysis of Current Evidence. Vaccines 2023, 11, 140. https://doi.org/10.3390/vaccines11010140
Torella M, Marrapodi MM, Ronsini C, Ruffolo AF, Braga A, Frigerio M, Amabile E, Vastarella MG, Rossi F, Riemma G. Risk of Premature Ovarian Insufficiency after Human Papilloma Virus Vaccination: A PRISMA Systematic Review and Meta-Analysis of Current Evidence. Vaccines. 2023; 11(1):140. https://doi.org/10.3390/vaccines11010140
Chicago/Turabian StyleTorella, Marco, Maria Maddalena Marrapodi, Carlo Ronsini, Alessandro Ferdinando Ruffolo, Andrea Braga, Matteo Frigerio, Emanuele Amabile, Maria Giovanna Vastarella, Francesca Rossi, and Gaetano Riemma. 2023. "Risk of Premature Ovarian Insufficiency after Human Papilloma Virus Vaccination: A PRISMA Systematic Review and Meta-Analysis of Current Evidence" Vaccines 11, no. 1: 140. https://doi.org/10.3390/vaccines11010140
APA StyleTorella, M., Marrapodi, M. M., Ronsini, C., Ruffolo, A. F., Braga, A., Frigerio, M., Amabile, E., Vastarella, M. G., Rossi, F., & Riemma, G. (2023). Risk of Premature Ovarian Insufficiency after Human Papilloma Virus Vaccination: A PRISMA Systematic Review and Meta-Analysis of Current Evidence. Vaccines, 11(1), 140. https://doi.org/10.3390/vaccines11010140